Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Endologix Inc (ELGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 55,863
  • Shares Outstanding, K 103,454
  • Annual Sales, $ 181,160 K
  • Annual Income, $ -66,400 K
  • 36-Month Beta 0.56
  • Price/Sales 0.28
  • Price/Cash Flow N/A
  • Price/Book 1.05
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.57
  • Most Recent Earnings -0.12 on 11/01/18
  • Next Earnings Date 02/25/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.21
  • Number of Estimates 5
  • High Estimate -0.15
  • Low Estimate -0.26
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -162.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.53 +1.89%
on 02/15/19
0.89 -39.66%
on 01/18/19
-0.24 (-30.77%)
since 01/15/19
3-Month
0.53 +1.89%
on 02/15/19
1.04 -48.08%
on 11/19/18
-0.46 (-46.00%)
since 11/15/18
52-Week
0.53 +1.89%
on 02/15/19
6.72 -91.96%
on 06/15/18
-3.67 (-87.17%)
since 02/15/18

Most Recent Stories

More News
WellCare Health (WCG) Q4 Earnings Beat Estimates, Soar Y/Y

WellCare Health's (WCG) Q4 earnings gain from Meridian buyout and growth in membership.

MOH : 135.34 (-0.54%)
ELGX : 0.54 (unch)
WCG : 279.15 (+1.99%)
THC : 24.47 (+2.64%)
Humana's (HUM) Q4 Earnings Surpass Estimates, Improve Y/Y

Humana's (HUM) fourth-quarter earnings gain on the back of Medicare Advantage membership growth and operating efficiencies.

HUM : 310.30 (+2.90%)
MOH : 135.34 (-0.54%)
ELGX : 0.54 (unch)
THC : 24.47 (+2.64%)
Centene's (CNC) Earnings Top Estimates in Q4, Surge Y/Y

Centene's (CNC) Q4 earnings ride high on robust revenues, solid acquisitions and stronger Health Insurance Marketplace business.

MOH : 135.34 (-0.54%)
ELGX : 0.54 (unch)
CNC : 64.97 (+1.58%)
THC : 24.47 (+2.64%)
Endologix, Inc. to Announce Fourth Quarter and Fiscal Year 2018 Financial Results on February 25, 2019

Endologix, Inc.(Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the fourth quarter and fiscal...

ELGX : 0.54 (unch)
Endologix Provides Update on Previously Announced Voluntary Nellix System Recall

Endologix(R) Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the EC Certificate of Conformity (CE Mark) for the Nellix EndoVascular...

ELGX : 0.54 (unch)
Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix, Inc. (Nasdaq: ELGX) (the "Company"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to a newly hired...

ELGX : 0.54 (unch)
Endologix Appoints John D. Zehren as Chief Commercial Officer

Endologix, Inc. (Nasdaq:ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed John D. Zehren...

ELGX : 0.54 (unch)
Endologix Announces Fourth Quarter and Full-Year 2018 Preliminary Financial Results and Provides 2019 Financial Guidance

Endologix, Inc. (the "Company") (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the fourth...

ELGX : 0.54 (unch)
Endologix Takes Decisive Action to Optimize Patient Outcomes by Ensuring Nellix System Used Only within Current Indications

--Decision Aligns with European Society for Vascular Surgery Practice Guidelines

ELGX : 0.54 (unch)
Endologix, Inc. to Present at the J.P. Morgan Healthcare Conference

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John Onopchenko, Chief Executive Officer, and Vaseem Mahboob,...

JPM : 105.55 (+3.06%)
ELGX : 0.54 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade ELGX with:

Business Summary

Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment...

See More

Key Turning Points

2nd Resistance Point 0.57
1st Resistance Point 0.56
Last Price 0.54
1st Support Level 0.53
2nd Support Level 0.51

See More

52-Week High 6.72
Fibonacci 61.8% 4.36
Fibonacci 50% 3.63
Fibonacci 38.2% 2.89
Last Price 0.54
52-Week Low 0.53

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar